Crossmark

Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study

Published Online: 2021-11-22

Published Print: 2022-01

Authors

Kelton, Kari

Klein, Tim

Murphy, Dan

Belger, Mark

Hille, Erik

McCollam, Patrick L.

Spiro, Theodore

Burge, Russel https://orcid.org/0000-0001-7907-6400
Funding

Funding for this research was provided by:

Eli Lilly and Company
License Information

Text and Data Mining valid from 2021-11-22

Version of Record valid from 2021-11-22
More Information

Article History

Received: 20 September 2021

Accepted: 29 October 2021

First Online: 22 November 2021

Document is current